Correlation between the DNA global methylation status and progesterone receptor expression in normal endometrium, endometrioid adenocarcinoma and precursors

Virchows Archiv : an International Journal of Pathology
Lina GhabreauLucien Frappart

Abstract

Endometrial carcinomas are the most common malignancy of the female genital tract and the third most common cancer in women. Progesterone and oestrogen receptors (PRs, ERs) are the most widely documented prognostic and predictive factors in endometrioid adenocarcinoma. Besides the hormonal pathway involved in the progression of preneoplastic and neoplastic lesions, alterations of the DNA methylation status have been shown to be an early signal of tumorigenesis. In this study, we show that in normal endometrium, during the proliferative phase, DNA methylation and PR expression are high, with a significant decline towards the end of the secretory phase and a gradual increase in non-atypical and atypical endometrial hyperplasia; they reach their highest level in grade I, then decrease significantly in grade-II and grade-III endometrioid adenocarcinomas. During each stage, a significant positive correlation is observed between DNA methylation and PR (P<0.0001). The strong parallelism between DNA methylation and PR expression precludes establishing a precise determination regarding the timing of these events, clearly involved in the genesis of endometrioid adenocarcinoma.

Citations

Nov 10, 2011·Molecular and Cellular Endocrinology·Sun-Wei Guo
Apr 17, 2010·Obstetrics and Gynecology International·Tsuyoshi OkudaTakashi Okai
Oct 26, 2010·Fertility and Sterility·Zoë L VincentAnna P Ponnampalam
May 5, 2017·Epigenomics·Carla BartoschCarmen Jerónimo
Apr 12, 2008·International Journal of Cancer. Journal International Du Cancer·Xiaoyun LiaoAnnie Nga-Yin Cheung
May 15, 2012·Reproduction : the Official Journal of the Society for the Study of Fertility·Y B DingY X Wang
Jun 12, 2012·International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society·Qian HuQin-ping Liao
Jun 6, 2008·Applied Immunohistochemistry & Molecular Morphology : AIMM·Kimberly H AllisonRochelle L Garica
Feb 9, 2010·Molecular Human Reproduction·S K MunroA P Ponnampalam
Jun 1, 2014·Molecular Endocrinology·Sahar HoushdaranLinda C Giudice
Oct 9, 2019·American Journal of Reproductive Immunology : AJRI·Amruta D S Pathare, Indira Hinduja
Nov 22, 2019·Molecular Reproduction and Development·Vishakha MahajanAnna P Ponnampalam
Dec 7, 2016·Human Reproduction Update·Peter A SandersonPhilippa T K Saunders
Jul 29, 2019·Cellular and Molecular Life Sciences : CMLS·Shuangbo KongJinhua Lu
Apr 4, 2021·International Journal of Molecular Sciences·Roberto PiergentiliFederica Perelli
May 22, 2020·Molecular and Cellular Endocrinology·M M MilesiJ Varayoud
May 27, 2021·Clinical Epigenetics·Alejandra Monserrat Retis-ResendizEdgar Ricardo Vázquez-Martínez

❮ Previous
Next ❯

Related Concepts

Related Feeds

Cancer Epigenetics & Metabolism (Keystone)

Epigenetic changes are present and dysregulated in many cancers, including DNA methylation, non-coding RNA segments and post-translational protein modifications. The epigenetic changes may or may not provide advantages for the cancer cells. This feed focuses on the relationship between cell metabolism, epigenetics and tumor differentiation.

Cancer Epigenetics & Methyl-CpG (Keystone)

Epigenetic changes are present and dysregulated in many cancers, including DNA methylation, non-coding RNA segments and post-translational protein modifications. Here is the latest research on cancer epigenetics and methyl-CpG binding proteins including ZBTB38.

Cancer Epigenetics and Senescence (Keystone)

Epigenetic changes are present and dysregulated in many cancers, including DNA methylation, non-coding RNA segments and post-translational protein modifications. The epigenetic changes may be involved in regulating senescence in cancer cells. This feed captures the latest research on cancer epigenetics and senescence.

Cancer Epigenetics (Keystone)

Epigenetic changes are present and dysregulated in many cancers, including DNA methylation, non-coding RNA segments and post-translational protein modifications. The epigenetic changes may or may not provide advantages for the cancer cells. Here is the latest research on cancer epigenetics.

Cancer Epigenetics

Epigenetic changes are present and dysregulated in many cancers, including DNA methylation, non-coding RNA segments and post-translational protein modifications. The epigenetic changes may or may not provide advantages for the cancer cells. Here is the latest research on cancer epigenetics.

Cell Signaling & Cancer Epigenetics (Keystone)

Epigenetic changes are present and dysregulated in many cancers, including DNA methylation, non-coding RNA segments and post-translational protein modifications. This feed covers the latest research on signaling and epigenetics in cell growth and cancer.